Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | FOS | P01100 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426917 | 0.89 | NFE2L2 (0.47) | ALDH1A1LMNASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL5408991 | 0.89 | LMNA (0.45) | ALDH1A1LMNASMN1; SMN2ABCG2MAOB | |
| SCHEMBL5415606 | 0.87 | NFE2L2 (0.53) | ALDH1A1MEN1TP53MAPTKMT2A | |
| SCHEMBL5423015 | 0.86 | STAT3 (0.45) | ALDH1A1LMNASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL27738946 | 0.86 | STAT3 (0.45) | ALDH1A1LMNASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL27739136 | 0.85 | PTGS2 (0.43) | ALDH1A1LMNASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL5411190 | 0.85 | PTGS2 (0.43) | ALDH1A1LMNASMN1; SMN2KDM4EMEN1 | |
| SCHEMBL5411235 | 0.85 | ABCG2 (0.43) | ALDH1A1LMNASMN1; SMN2KDM4EKMT2A | |
| SCHEMBL5426609 | 0.82 | NFE2L2 (0.47) | ALDH1A1KDM4EMEN1GAAKMT2A | |
| SCHEMBL4619301 | 0.81 | LMNA (0.48) | ALDH1A1LMNASMN1; SMN2KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888519-A2 | STYRYLSULFONAMIDES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-02-20 | — | — | EP | claimed |
| WO-2007054139-A2 | STYRYLSULFONAMIDES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | claimed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | claimed |
| EP-1888519-A2 | STYRYLSULFONAMIDES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007054139-A2 | STYRYLSULFONAMIDES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-18 | — | — | WO | disclosed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270874-A1 | Styrylsulfonamides | STS, SULT1E1, BRCA1 | ALDH1A1 196/4885LMNA 1178/4885SMN1; SMN2 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.